Zoldonrasib treatment led to an objective response rate of 52%, a disease control rate of 93%, and a favorable safety and tolerability pr...

Back to meeting Original

Back to meeting

AACR· @AACR · X·2026-04-20 02:33· 2026-04-20Score60

zoldonrasib

Reading

KRAS / RAS targeting: from platform to Phase 3

zoldonrasib and VS-7375 in G12D remain Phase 1 — strong numbers, small samples, not head-to-head.

Body

Zoldonrasib treatment led to an objective response rate of 52%, a disease control rate of 93%, and a favorable safety and tolerability profile. #AACR26

Heat 1 · 1 like · 0 replies · 0 reposts

Source: AACR · x.com